Publications by authors named "Christopher Mensch"

Article Synopsis
  • * A new antiviral strategy using an inhaled recombinant viral trap that combines multiple ACE2 proteins shows strong effectiveness against various SARS-CoV-2 variants and other coronaviruses.
  • * This ACE2 decameric viral trap can be used both before and after infection, is stable for over twelve weeks at room temperature, and proves protective in animal studies, indicating promise for future pandemic responses.
View Article and Find Full Text PDF

Despite a consistent benefit of existing pneumococcal conjugate vaccine (PCV) on invasive pneumococcal disease and pneumonia across different epidemiological settings a tremendous gap exists towards global PCV coverage. Currently, no lyophilized dosage form exists in the PCV global vaccine marketplace and currently licensed vaccines target some, but not all relevant serotypes of Streptococcus pneumoniae. The development of lyophilized presentations of an adjuvanted multivalent vaccine formulation that aligns with the evolving epidemiological assessment of the pneumococcal disease offers broader coverage with distinct cold chain and thermostability advantages.

View Article and Find Full Text PDF

Aluminum-containing adjuvants have been widely used in vaccine formulations to safely and effectively potentiate the immune response. The examination of the extent of antigen adsorption to aluminum adjuvant is always evaluated during the development of aluminum adjuvant containing vaccines. A rapid, automated, high-throughput assay was developed to measure antigen adsorption in a 96-well plate format using a TECAN Freedom EVO (TECAN).

View Article and Find Full Text PDF
Article Synopsis
  • Vaccine thermal stability relies on formulation factors like pH and ionic strength, which can be predicted based on scientific knowledge and experience.
  • Support from experimental data is necessary for regulators to validate stability claims, as predictions alone are insufficient.
  • The Design of Experiment (DoE) approach enables deeper understanding of how these formulation factors affect thermal stability, even in cases where the underlying mechanisms are not fully understood; this was exemplified in a study of an aluminum adjuvant vaccine showing formulation differences within just 15 days.
View Article and Find Full Text PDF

Unlabelled: The purpose of this work was to investigate the susceptibility of an aluminum adjuvant and an aluminum-adjuvanted native outer membrane vesicle (nOMV) vaccine formulation to freeze/thaw-induced agglomeration using static light scattering and micro-flow Imaging analysis; and to evaluate the use of propylene glycol as a vaccine formulation excipient by which freeze/thaw-induced agglomeration of a nOMV vaccine formulation could be mitigated. Our results indicate that including 7% v/v propylene glycol in an nOMV containing aluminum adjuvanted vaccine formulation, mitigates freeze/thaw-induced agglomeration.

Lay Abstract: We evaluated the effect of freeze-thawing on an aluminum adjuvant and an aluminum adjuvanted native outer membrane vesicle (nOMV) vaccine formulation.

View Article and Find Full Text PDF

The toxicity of Clostridium difficile large clostridial toxin B (TcdB) can be reduced by many orders of magnitude by a combination of targeted point mutations. However, a TcdB mutant with five point mutations (referred to herein as mTcdB) still has residual toxicity that can be detected in cell-based assays and in-vivo mouse toxicity assays. This residual toxicity can be effectively removed by treatment with formaldehyde in solution.

View Article and Find Full Text PDF

Unlabelled: TECHNICAL ABSTRACT: The purpose of this work was to investigate a potential mechanism for the inhibition of tungsten-mediated monoclonal antibody (mAb) biophysical modifications and sub-visible particle formation. A 1 mg/mL mAb formulated in 150 mM NaCl, 20 mM histidine, pH 6.0, was incubated with 1, 37, and 100 ppm of tungsten polyanions in the form of sodium tungstate both in the presence and absence of the anionic surfactant and chelating agent diethylene triamine pentaacetic acid (DTPA) or the cationic surfactant cetyl trimethyl ammonium bromide (CTAB) for 24 h at 25 °C.

View Article and Find Full Text PDF

Freezing and thawing of vaccines containing aluminum adjuvants can lead to formation of aggregates and loss in vaccine potency. We sought to understand whether and to what extent the freeze-thaw damage to aluminum adjuvants would differ based on suspension state (flocculation and settlement) at the time of freezing. As flocculation and settlement characteristics of aluminum adjuvants are driven largely by the electrostatic charges on the adjuvant particles, which, in turn, are strongly influenced by the pH of the suspension, we conducted freeze-thaw studies on both Adjuphos and Alhydrogel™ samples at three pH levels (4, 6.

View Article and Find Full Text PDF